NCT03797014View on ClinicalTrials.gov

B/F/TAF Switch Study for HIV-HBV Coinfection

PHASE4CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

November 22, 2022

Study Completion Date

May 5, 2023

Conditions
HIV-1-infectionHepatitis B
Interventions
DRUG

B/F/TAF

Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.

Trial Locations (2)

19114

Newlands Health, Philadelphia

21201

Institute of Human Virology Clinical Research Unit, Baltimore

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

University of Maryland, Baltimore

OTHER